Therapy assessment in prostate cancer using imaging surrogate markers for the PI3K-AKT-mTORC- and AR-pathway (B11*)

• Subject Area: Nuclear Medicine, Radiotherapy, Radiobiology
• Term: from 2017 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 68647618

Recurrent prostate cancer commonly being treated with different androgen-receptor(AR)-modulating agents is highly expressing the prostate-specific-membrane-antigen (PSMA) constituting an ideal target for imaging and radioligand therapy. The primary aim of this project is to investigate PSMA-ligand PET as potential surrogate marker for activity of the PI3K-AKT-mTORC and AR-receptor axis and to develop and evaluate probes for differentiation of androgen-dependent (AD) and CRPC (κ-opioid receptor agonists, Prostatic Acid Phosphatase). Potential pre-targeting of PSMA under AR-targeted therapy as well as additive effect of radiosensitizer on PSMA radioligand therapy will be assessed.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 824: Imaging for Selection, Monitoring and Individualisation of Cancer Therapies
• Applicant Institution: Technische Universität München (TUM)
• Project Heads: Professor Dr. Matthias Eiber; Professor Dr. Hans-Jürgen Wester